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Effect of antenatal corticosteroids on morbidity and mortality in preterm 
singletons and twins. 
 
 
Abstract  
 
Purpose: Compare the effect of antenatal corticosteroids (ACS) on neonatal 
outcomes among singleton and twin pregnancies and the impact of completeness 
and timing of ministration. 
Materials and Methods: Retrospective cohort study involving 951 preterm deliveries 
(25+0-34+6weeks), between 2006 and 2015. Neonatal outcomes were evaluated 
according to completeness of ACS ("Complete" n=441;"Rescue" n=38;"Incomplete" 
n=175;"No ACS" n=98) and timing of therapy related to delivery ("Before 7 days" 
n=260; "After 7 days" n=181).  
Results: On Respiratory Distress Syndrome (RDS), odds ratio (OR) for twins was 
0.172, 95% confidence interval (CI) 0.047;0.591 and for singletons 0.390 (95%CI 
0.214;0.703) for complete or rescue courses, and 0.280 (95%CI 0.069;1.066) for 
twins and 0.906 (95%CI 0.482;1.698) for singletons for incomplete courses. About the 
need for mechanical ventilation (MV), twins had OR of 0.189 (95%CI 0.052;0.642)  
and singletons of 0.404 (95%CI 0.222;0.727) for complete or rescue courses and 
twins had OR=0.225 (95%CI 0.053;0.874) and singletons of 0.404 (95%CI 
0.222;0.727) for incomplete courses. About timing, group "After 7 days" had OR=2.00 
for RDS (95%CI 1.21;3.30) and 2.32 (95%CI 1.42;3.78) for MV. 
Conclusion: ACS improves neonatal outcomes both in singleton and twins. 
Delivering seven days after a complete course decreased neonatal morbidity. 
 
Key Words: 
Antenatal corticosteroids; twins; preterm; morbidity. 
 
 
  
Introduction 
 
 Preterm birth is the most costly complication of pregnancy and the leading cause of 
neonatal morbidity and mortality.[1,2] There are multiple strategies to minimize the risk and the 
impact of prematurity, such as ministration of antenatal corticosteroids (ACS), in association 
with tocolysis, neuroprotection with magnesium sulphate, and neonatal life-saving 
therapies.[3] These interventions improve neonatal survival after preterm birth.[4] 
 Since Liggins and Howie[5], numerous investigations have been conducted to 
ascertain the effect of ACS on prevention of neonatal morbidity and mortality in singleton 
pregnancies; nowadays, ACS are the cornerstone of prophylactic treatment in preterm birth, 
between 24+0 and 34+6 weeks of gestational age (GA), and its ministration is recommended 
by the National Institute of Health[2], the American College of Obstetricians and 
Gynecologists[6] and the Royal College of Obstetricians and Gynecologists[7]. When 
administered prior to preterm birth, ACS are not only effective in preventing respiratory 
distress syndrome (RDS) but also in reducing other complications of prematurity, such as 
intraventricular haemorrhage (IVH), retinopathy of prematurity (ROP), sepsis and necrotizing 
enterocolitis (NEC), and also neonatal mortality [3,4].Authors believe that, in order to achieve 
maximum effect, the ideal timing of delivery must occur between 24h and seven days after 
the last dose of therapy.[1,3,4,6,7]  
 Despite the significant amount of evidence supporting the impact of ACS in singleton 
pregnancies between 24 and 34+6 weeks of GA, there's a substantial lack of information 
regarding twin pregnancies.[8] The beneficial effect in singletons has justified ACS use in twin 
pregnancies, as the mechanism of action is likely to be the same, however the evidence is 
less robust.[1,4,7,9,10].  
 We aim to compare the effect of ACS in singleton and twin pregnancies in different 
neonatal outcomes. We have also tried to investigate the impact of therapeutic completeness 
(complete, incomplete or rescue) and timing (birth before or after seven days after the last 
ACS dose). 
 
 
 
 
 
 
 
 
 
 
Materials and Methods  
 
  We performed a retrospective cohort study at Centro Hospitalar de São João, a 
tertiary level hospital in Portugal, with average 2500 deliveries per year, preterm (<37 weeks) 
rate of 10% and very preterm (<32 weeks) of 2%.  
 Maternal demographic and obstetric characteristics and neonatal outcomes of all 
singleton and twin pregnant women with preterm deliveries between 25 and 34+6 weeks from 
January 2006 to December 2015 (n=951) were evaluated. After the approval of the Ethics 
Committee of the hospital, medical records of both mothers and newborns were reviewed 
separately.  
 We excluded pregnancies with complications such as twin-to-twin transfusion 
syndrome (n=19), major fetal defects (n=65),  triplet gestations (n=5) and women whose 
clinical records had important lack of information (n=25) or follow up losses (n=46).In order to 
increase internal validity, we eliminated pregnant women with less than 25 weeks of GA on 
admission (n=39) since none was exposed to ACS. 
  Maternal education, maternal age, body mass index (BMI), smoking habits, alcohol 
or drug abuse, parity, GA on admission and at the time of delivery, the mode of delivery, 
chorionicity in twins, abruptio placenta, fetal growth restriction (defined by Fenton`s growth 
charts [11]), fetal Doppler abnormalities, polihydramnios/oligohydramnios, preterm premature 
rupture of membranes (PPROM), diabetes, hypertensive, auto immune and thyroid diseases 
were evaluated. 
 We ascertained whether the mother received ACS, at which GA, the type of ACS, if 
the course completeness and the time interval (in days) between the first ministration and 
delivery, registering the same data for rescue courses. A course of ACS consisted on four 
6mg doses of intramuscular dexamethasone at 12h intervals or two 12mg doses of 
intramuscular betamethasone at 24h interval, as the effect of these two types of ACS is 
apparently similar[2]. In our study, the ACS used before February 2014 was betamethasone, 
and since March 2014, dexamethasone.  
 For analysis, we divided this population in two major groups: "No ACS" group 
included pregnant women that were not submitted to antenatal corticosteroids (n=98) and the 
"ACS" group women exposed to this therapy (n=654). "ACS" group was divided in three 
subgroups according to ACS completeness: "Complete" (women that had a complete course 
of ACS (n=441)), "Incomplete" (women submittted to less than the recommended dose 
(n=175)) and "Rescue" (women that had a complete or incomplete course of ACS, followed 
by another complete course two to three weeks after the first one (n=38)). 
Our primary outcomes were Respiratory Distress Syndrome (RDS), diagnosed 
according to the criteria of the Update on the European Consensus Guidelines on the 
Management of Neonatal Respiratory Distress Syndrome in Preterm Infants (2013) [12] and 
the need for mechanic ventilation (MV). Secondary outcomes were neonatal death (defined 
as death in the first 28 days of life), admission to the NICU (Neonatal Intensive Care Unit), 
Apgar Index at the 1st and 5th minute of life, arterial pH value at birth, NEC (defined by the 
modified Bell staging criteria[13]), IVH (diagnosed and staged based on Papile classification 
[14]), sepsis, ROP (diagnosed and graded by the International Classification of Retinopathy of 
Prematurity revisited[15]) and need for phototherapy. We also performed a composite of 
neonatal morbidity that included RDS, NEC, ROP, IVH, sepsis and need for admission in the 
NICU. 
 The association between ACS and neonatal outcomes was evaluated for singletons 
and twins and adjusted for GA at delivery, weight of newborn and type of pregnancy 
(singleton vs. twins). For dichotomous neonatal outcomes, due the smaller sample size, the 
subgroups "Complete" and "Rescue" were grouped as one. 
 We also performed a subanalysis with the subgroup "Complete", subsequently 
divided in class "After 7 days" (if the birth happened more that seven days after the 
conclusion of the course) and  "Before 7 days" (birth in the first seven days after completing 
the course).As we had only two participants that delivered prior to 24h after the last dose of 
ACS, we only separated the participants in 2 groups. Results for this analysis are presented 
in general due to loss of statistical power among twins and are adjusted for GA at delivery 
and weight of the newborn.  
 For continuous outcomes we used linear mixed effects analysis with random intercept 
per birth, when twins were included, and generalized least squares when twins were not 
included. Linear regression coefficients and the respective 95% confidence interval (95%CI) 
were used to estimate the association between the exposure and the respective outcome. A 
final model was estimated that included an interaction term between ACS group and being 
twin. For categorical outcomes we used unconditional logistic regression to estimate the 
odds ratios and the respective 95%CI. In twins, the data was aggregated and the outcome 
had considered when at least one of the twins had the outcome.  
 
 
 
 
 
 
 
Results 
 
 In our study, 752 pregnancies were eligible from a total of 951 (79,1%); 199 were 
excluded by the aforementioned exclusion criteria. As so, 131 twins pregnancies and 621 
singleton pregnancies were evaluated: 98 included in the "No ACS" group (76 singleton and 
22 twins pregnancies), and 654 on the "ACS" group (545 singleton and 109 twins 
pregnancies). In this last group, 441 were in the "Complete" subgroup, 175  in the 
"Incomplete" and 38 in the "Rescue" subgroup. The pregnancies included in the "Complete" 
subgroup were then categorized according to timing as "After 7 days" (n=181) or "Before 7 
days" (n=260). 
 The groups "No ACS" and "ACS" were similar regarding baseline maternal 
demographic and obstetric characteristics, except for chorioamnionitis, FGR, fetal Doppler 
abnormalities, mode of delivery and GA at admission (table 1). 
 Neonatal continuous outcomes according to ACS regimens are shown in table 2- in 
the composite of neonatal morbidity, twins had beta values (β) of -0.226 (95%CI -
0.588;0.139) and singletons of -0.312 (95%CI -0.536; -0.088) if exposed to complete courses 
and β values of 0.044 (95%CI -0.364;0.451) in twins and 0.173 (95%CI 0.072;0.418) in 
singletons when exposed to incomplete courses. 
 For dichotomous neonatal outcomes, about need for admission in NICU, in 
singletons the odds ratio (OR) for complete or rescue courses was 0.887 (95%CI 
0.427;1.740) and for incomplete courses 6.217(95%CI 2.212;20.265) and in twins OR for 
complete or rescue courses was 1.061(95%CI 0.286;3.528) and for incomplete courses 
7.381(95%CI 1.046;149.349). Regarding RDS, in singletons OR for complete or rescue 
courses was 0.390 (95%CI 0.214;0.703) and for incomplete courses 0.906(95%CI 
0.482;1.698) and in twins OR for complete or rescue courses was 0.172(95%CI 0.047;0.591) 
and for incomplete courses 0.280(95%CI 0.069;1.066); about the need for phototherapy, in 
singletons OR for complete or rescue courses was 1.261 (95%CI 0.865; 1.86) and for 
incomplete courses 1.515(95%CI 1.010;2.294) and in twins (OR for complete or rescue 
courses was 0.813(95%CI 0.270;2.287) and for incomplete courses 1.252(95%CI 
0.367;4.180). Concerning MV need, in singletons OR for complete or rescue courses was 
0.404(95%CI 0.222;0.727) and for incomplete courses 0.819(95%CI 0.435;1.535) and in 
twins OR for complete or rescue courses was 0.189(95%CI 0.052;0.642) and for incomplete 
courses 0.225 (95%CI 0.053;0.874). We couldn't find significant  differences for the variables 
neonatal death, NEC, IVH, ROP and sepsis. 
 Neonatal outcomes according to timing are shown in table 3: in RDS, the OR for 
the group "After 7 days" was 2 (95%CI 1.21;3.30), and in almost all analyzed variables this 
group was positively associated with adverse outcomes.     
 
Discussion 
 
 Improving pregnancy outcomes is a major goal of healthcare today, and with ACS 
many premature lives have been saved. The success of this therapy is explained by the fact 
that synthetic glucocorticoids mimic the developmental maturational changes that normally 
occur in late gestation in response to rising fetal glucocorticoids. 
 Despite abundant evidence that use of ACS in singleton pregnant women who are in 
risk of PTL, between 24 and 34+6 weeks, has important benefits, data in twin pregnancies the 
data is limited [1,3,4,7,8-10,16-20].  
 Our main research question was to determine if clinical neonatal outcomes were 
equivalent when women received the same therapeutic scheme, independently of plurality.  
 We started to evaluate maternal characteristics (table 1): in 26 parameters, only in 
five (incidence of chorioamnionitis, fetal growth restriction (FGR), Fetal Doppler 
abnormalities, mode of delivery and mean GA at admission) there was significant differences 
between the "No ACS" and the "ACS" group. The higher rate of chorioamnionitis in the "No 
ACS" group may possibly be explained by less usage of ACS in these patients. FGR and 
fetal Doppler abnormalities were more common in the “ACS” group possibly because there's 
a more aggressive treatment in this higher risk groups. Regarding the mode of delivery, the 
majority of the vaginal preterm births occurred amongst women in the "No ACS" group (in 
fact, being already in labour was the main reason for not receiving ACS between our 
participants) with high rates of caesarean delivery in the "ACS" group. Furthermore, we 
analyzed the frequency of elective and urgent caesareans, and probably because these were 
the most severe cases of fetal compromise, results showed that the majority of urgent 
caesareans occurred in the "No ACS" group. Since the association between ACS and 
neonatal outcomes was not changed after inclusion of mode of delivery in the multivariable 
model, the final analysis wasn't adjusted for this characteristic.  
 We analyzed the impact of ACS completeness and timing of delivery. In general, and 
about the completeness, having a complete or rescue course was better than an incomplete 
course or no treatment, which may be attributed to inadequate dose or duration of exposure, 
as it was shown in other studies[21]. About the impact of different timings between the last 
ACS dose and delivery, the analysis wasn’t able to compare singletons with twins because of 
our sample size, but the absence of statistical interaction lead us to the presupposition that 
the effect is similar between this two groups. Delivery in the first seven days after conclusion 
of this therapy was significantly associated with lower probability of neonatal death, RDS and 
need for MV, and despite no statistical significance, other outcomes were compatible, 
suggesting lower probabilities of developing NEC, need for phototherapy or admission to 
NICU, and also higher values of umbilical arterial pH, Apgar index at 1st and 5th minute of 
life and number of days at NICU. Though, the IVH was an exception: our results suggest that 
newborns delivered more than seven days after ministration had lower rates of this disease, 
a finding perhaps circumstantial but that can also be explained by the fact the higher GAs at 
admission are associated with lower prematurity associated complications. Our results in the 
timing sub analysis are also compatible with literature: Blickstein et al.[22] found that if the 
delivery occurred seven days past the ministration, there was no effect in the reduction of 
RDS, in comparison with delivering in the first seven days, both singleton and twins. 
Moreover, Gyamfi et al[10] agreed by demonstrating that concentrations of betamethasone in 
cord blood decreased over time, irrespective to plurality. 
   However, our main research question was to evaluated if results in twins were 
comparable to singletons. Although in singletons there's a generalized consensus of 
administration of ACS, twins are treated by extrapolation. In the set of continuous variables, 
participants were divided in the three subgroups aforesaid ("Complete", "Incomplete" and 
"Rescue"). In the composite of neonatal morbidity, Apgar indexes and number of days at 
NICU, there were no differences between singletons and twins, so we believe that the effect 
of complete courses was equally protective. About the NICU admission, RDS, need for 
phototherapy and MV, in both singleton and twins doing a rescue or complete course was 
better than doing an incomplete one, which was also better than no treatment at all. When 
evaluating the difference of impact of ACS completeness in twins versus singletons [23], we 
found that concerning admission in NICU, the association was 20% lower, so we believe that 
effect is similar in singletons and twins. In respect of RDS, as the association was 43% 
higher in singletons, we report that when twin pregnancies are submitted to complete 
regimens, they have less risk of developing this condition, in comparison with singletons. 
Also, about the need for MV and phototherapy, the difference was of 46% and 67%, 
respectively, with higher protection in twin pregnancies. So, our results suggest that despite 
ACS protection both in singletons and twins, on respect of respiratory outcomes, twins may 
possibly be more protected. 
 Authors suggest that ACS ministration doesn't reduce the incidence of RDS in 
preterm twins as it does in singletons, so that there's an interaction with plurality [1, 3,16-18] . 
Because the recommended dose of ACS is administered irrespective of maternal mass or 
fetal number, it has been hypothesized that the supposed suboptimal benefits of ACS 
treatment in twin pregnancies may be attributable to greater degrees of maternal 
physiological changes in twin pregnancies, such as greater maternal blood volume 
expansion and different clearance of betamethasone[24].  
 However, this hypothesis was challenged by recent studies that demonstrated no 
difference between either the pharmacokinetics (clearance and volume of distribution) or the 
maternal serum or cord blood concentrations between singletons and twins[10,19]. Other 
studies report that the effect of ACS is present in twin pregnancies, so that the actual dosage 
and timing is effective [1,8,9,19,20]. Recently, Salim et al. demonstrated that serum 
betamethasone concentration is measurable with ELISA kit, paving the way for future 
investigations to determine the optimum concentration that would be clinically[25]. 
 Our results are in this perspective too: apparently the number of fetus isn't a 
determinant of the effect of this therapy in the majority of our evaluated outcomes, so that 
giving this therapy to singleton or twin pregnant women seems to produce the same effects. 
We also highlight that, in the respiratory outcomes, when exposed to the same therapeutic 
scheme, twins were even more protected. However, there's still need to be sure which 
dosage of ACS is effective not only in singletons but mostly in twin pregnancies.   
 Our study had several strengths: the inclusion criteria were broad, and the analysis 
did not exclude fetal abnormalities compatible with life. In contrast to other studies examining 
neonatal outcomes, we included detailed antenatal and pregnancy characteristics. Though, 
the inherent weaknesses of a cohort study design should be recognized: the retrospective 
nature invites the possibility of sampling bias leading to differences in major adverse 
outcome measures. Also, the number of patients was not large enough to allow us to have 
statistically significant results in all of our outcomes, which is not unique to our study.  
 Although we think it would be important to differentiate between mono and dichorionic 
twin pregnancies, we did not have enough sample size to perform this analysis.  Further 
observational studies in large cohorts of twins are warranted to increase the power to find 
differences in neonatal outcomes, as well as increase our confidence in the safety of using 
this dose and timing of ACS in twin pregnancies, but we highlight the possible ethical issues 
that may rise with the omission of therapy to the "control" group. A large, randomized, 
prospective trial would evaluate the difference of impact of the corticotherapy in singleton 
and twin pregnancy.. 
 In conclusion, there were differences in the effect of ACS between singletons and 
twins in RDS, need for MV and phototherapy. 
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Table 1: Maternal Demographic and Obstetric Charateristics.  
 
 
 
 
TOTAL NO ACS (n (%)) ACS (n (%)) p value 
Years of education  
   
0.931 
<12 years 276 34 (12.3) 242 (87.7) 
 
> 12 years 432 51 (11.8) 381 (88.2) 
 
Tobacco 
   
0.867 
Yes 50 7 (14.0) 43 (86.0) 
 
Alcohol 
   
0.379 
Yes 6 2 (33.3) 4 (66.7) 
 
Drugs 
   
0.270 
Yes 1 1 (100) 0 (0) 
 
Parity 
   
0.927 
Nulliparous 361 46 (12.7) 315 (87.3) 
 
Multiparous 393 52 ( 13.2) 341 (86.8) 
 
Conception 
   
0.255 
Not Spontaneous 75 6 (8.0) 69 (92.0) 
 
Spontaneous 665 89 (13.4) 576 (86.6) 
 
DM 
   
0.788 
Yes 87 10 (11.5) 77 (88.5) 
 
Hypertensive Disease 
   
0.383 
Yes 176 19 (10.8) 157 (89.2) 
 
Mode of Delivery 
   
<0.001 
Vaginal 37 11 (29.7) 26 (70.3) 
 
Urgent Cesariane 323 44 (13.6) 279 (86.4) 
 
Eletive Cesariane 123 7 (5.70 116(94.3) 
 
Polihydramnios/Oligohydramnios   
   
0.102 
Yes 115 9(7.8) 106(92.2)  
PPROM    0.346 
Yes 253 28 (11.1) 225 (88.9)  
Abruptio Placenta     0.093 
Yes 39 9 (23.1) 30 ( 76.9)  
FGR    0.014  
Yes 169 12(7.1) 157(92.9)  
DFA    0.005  
Yes 113 5 (4.4) 108(95.6)  
Thyroid pathology    0.879 
Yes 37 4 (10.8) 33 (89.2)  
Chorioamnionitis    0.036  
Yes 6 3 (50.0) 3 (50.0)  
Auto-Immune Diseases    0.819 
Yes 22 2 (9.1) 20 (90.9)  
 Mean (SD) Mean (SD) Mean (SD)  
Maternal Age 31.03 (5.91) 31.60 (6.436) 30.94 (5.833) 0.931 
Body Mass Index 26.57 (5.299) 27.57 (5.84) 26.438 (5.21) 0.115 
GA at admission 32.17 (2.56) 33.10 (2.38) 32.03 (2.56) <0.001  
 
DFA: Doppler blood  flow abnormalities; DM: Diabetes Mellitus; FGR: Fetal Growth 
Restriction; GA: Gestational Age  
 
 
  
 
 
 
Table 2: Impact of different ACS regimens in neonatal outcomes represented by continuous variables  
 
 
 
 
 TOTAL
1 
TWINS SINGLETON p 
interaction 
 β (95% CI) β (95% CI) β (95% CI)  
Apgar 1    0.760 
No ACS (Ref) Ref Ref Ref  
Complete 0.833(0.430;1.23) 1.18 (0.544;1.81) 0.707 (0.210;1.20)  
Incomplete 0.289 (-0.160;0.737) 0.289 (-0.434;1.01) 0.269 (-0.280;0.819)  
Rescue 1.419(0.737;2.10) 1.81(0.739;2.886) 1.30(0.467;2.15)  
Apgar 5    0.428 
No ACS(Ref) Ref Ref Ref  
Complete 0.627 (0.292;0.960) 0.759 (0.272;1.246) 0.573 (0.150;0.996)  
Incomplete 0.385 (0.014;0.756) 0.041 (-0.512;0.595) 0.489 (0.022;0.955)  
Rescue 1.214(0.651;1.77) 1.21(0.385;2.03) 1.237(0.522;1.951)  
pH    0.657 
No ACS(Ref) Ref Ref Ref  
Complete 0.051(0.014;0.090) 0.0248 (-0.023;0.0734) 0.060(0.013;0.107)  
Incomplete 0.020 (-0.022;0.062) -0.0245 (-
0.077;0.0286) 
0.034 (-0.079;0.085)  
Rescue 0.059(0.003;0.115) 0.0367(-0.036;0.101) 0.061(-0.008;0.130)  
Days at NICU    0.667 
No ACS(Ref) Ref Ref Ref  
Complete -3.19 (-7.81;1.44) -2.44 (-9.94;5.052) -2.98 (-8.61;2.64)  
Incomplete 0.484 (-4.67;5.63) -1.62 (-10.22;6.971) 1.47 (-4.74;7.69)  
Rescue -0.916(-8.74;6.91) 6.99(-5.73;19.73) -2.54 (-12.07;6.97)  
     
Composite    0.800 
No ACS Ref Ref Ref  
Complete -0.301 (-0.492; -0.110) -0.224 (-0.588; 0.139) -0.312 (-0.536 ; -
0.088) 
 
Incomplete 0.142 (-0.067; 0.352) 0.044 (-0.364 ; 0.451) 0.173 (-0.072 ; 
0.418) 
 
Rescue -0.297 (-0.596; 0.036) -0.166 (-0.766;0.434) -0.298 (-
0.670;0.074) 
 
 
 
β: beta-value; 95%CI: 95% Confidence Interval NICU: Neonatal Intensive Care Unit; Apgar1: Apgar 
Index at 1st minute of life; Apgar5: Apgar index at the 5th minute of life; Composite: Included RDS, 
NEC, IVH, ROP, sepsis and need for admission in the NICU. 
1 Adjusted for type of pregnancy (singleton or twins), gestational age at delivery and weight of the newborn. 
  
  
 
 
Table 3: Impact of different ACS timings in neonatal outcomes  
 
 
 
 β (95% CI) 
Apgar 1  
Before 7 days  Ref 
After 7 days -0.057 (-0.410;0.295)  
Apgar 5  
Before 7 days  Ref 
After 7 days -0.042 (-0.351;0.266) 
pH  
Before 7 days  Ref 
After 7 days -0.025 (-0.055;0.0055) 
Days at NICU  
Before 7 days  Ref 
After 7 days 0.826 (-3.332 ; 4.98) 
 OR (95% CI) 
NICU  
Before 7 days  Ref 
After 7 days 1.093 (0.631 ; 1.894)  
RDS  
Before 7 days  Ref 
After 7 days 2.00 (1.21;3.30) 
NEC  
Before 7 days  Ref 
After 7 days 1.56 (0.56;4.34) 
Photo  
Before 7 days  Ref 
After 7 days 1.075 (0.68 ; 1.70) 
IVH  
Before 7 days  Ref 
After 7 days 0.673 (0.233;1.94) 
Death  
Before 7 days  Ref 
After 7 days 2.20 (1.016;4.77) 
MV  
Before 7 days  Ref 
After 7 days 2.32 (1.42;3.78) 
 
 
β: beta-value; OR: Odds Ratio; 95%CI: 95% Confidence Interval; NICU: Neonatal Intensive Care Unit; 
Apgar1: Apgar Index at 1st minute of life; Apgar5: Apgar index at the 5th minute of life; RDS: 
Respiratory distress syndrome; NEC: Necrotizing enterocolitis; Photo: phototherapy; IVH: 
Intraventricular hemorrhage;  MV: Mechanical ventilation. Adjusted for type of pregnancy (singleton or 
twins) and weight of the newborn. 
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procedures which apply in their institution and country. The Code of Ethics of the World Medical 
Association (Declaration of Helsinki) represents a minimal requirement. Please click on Ethics and 
Consent for further information. 
 
File preparation and types 
Manuscripts are preferred in Microsoft Word format (.doc files). Documents must be double-spaced, with 
margins of one inch on all sides. Tables and figures should not appear in the main text, but should be 
uploaded as separate files and designated with the appropriate file type upon submission. References 
should be given in Council of Science Editors (CSE) Citation & Sequence format (see References 
section for examples). 
 
Structure of Paper 
Manuscripts should be structured into headed sections as follows: Title page, Abstract, Introduction, 
Methods, Results, Discussion, Acknowledgements, Declaration of Interest statement, References, 
Tables and Figures. Each section should begin on a new sheet and be identified with the shoulder 
heading. Other subsection headings within the main headings may be used but should be limited. 
 
Title Page 
A title page should be provided comprising the manuscript title plus the full names and affiliations of all 
authors involved in the preparation of the manuscript. One author should be clearly designated as the 
corresponding author and full contact information, including phone number and email address, provided 
for this person. A short title (no more than 20 letters) and Keywords (5-8) that are not in the title should 
also be included on the title page. The keywords will assist indexers in cross indexing your article. 
 
Abstract 
An abstract not exceeding 200 words should state the aim of the study, the main findings, and how the 
results were interpreted. Abstracts for Short Reports should not exceed 100 words. 
Instructions for preparing structured abstracts: 
Structured abstracts should be no more than 200 words and consist of four paragraphs under the 
headings: 
Objective A precise statement of the primary objectives of the study, including the primary focus (e.g. 
diagnosis, prognosis, prevention) and information concerning the specific population, test, or outcome 
being discussed. 
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Conclusions The conclusions and their clinical application; the need for new studies may be suggested. 
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Style 
Define abbreviations when they first occur in the manuscript and from there on use only the abbreviation. 
When many unusual abbreviations are used, list them alphabetically with their definitions on a separate 
page. Whenever standardized abbreviations are available, use those; create new abbreviations only if 
absolutely unavoidable. Use generic names for drugs.  
 
 
  
 
If identification of a brand name is wanted, insert it in parentheses together with the manufacturer's name 
and address after the first mention of the generic name, noting trademark (TM) or registered (®) if 
applicable. Scientific measurements should be given in SI units, except for blood pressure, which should 
be expressed in mmHg. 
 
Clinical Trials 
Where applicable, authors reporting phase II and phase III randomized controlled trials should refer to 
the CONSORT Statement (www.consort-statement.org) for recommendations to facilitate the complete 
and transparent reporting of trial findings. Reports that do not conform to the CONSORT guidelines may 
need to be revised before formal review. 
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